Top

30-05-2014 | Gout | Book Chapter | Article

5. Prevention and Treatment of Inflammation in Gout

Authors: Fernando Perez-Ruiz, Ana Maria Herrero-Beites

Abstract

Acute inflammation is the hallmark of gout. Whereas episodes of acute inflammation (EAIs) are the paradigm of gout, chronic inflammation is related to the deposition of monosodium urate crystals (MSUCs) that is mostly subclinical and may appear early and even prior to the very first symptom.

1. De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martin-Mola E. Diagnosis of gout in patients with asymptomatic hyperuricemia: a pilot ultrasound study. Ann Rheum Dis. 2011; 71:157-158.

2. Wright SA, Filippucci E, McVeigh C, et al. High resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis. 2007; 66:859-864.

3. Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford). 2011; 50:740-745.

4. Saseen JJ, Agashivala N, Allen RR, Ghushchyan V, Yadao AM, Nair KV. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012; 51: 2004-2012.

5. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012; 64:1447-1461.

6. Wortmann RL, MacDonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three Phase III trials. Clin Ther. 2010; 32:2386-2397.

7. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009; 48:188-194.

8. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450-2461.

9. Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011; 306:711-720.

10. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65:1312-1324.

11. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012; 125:1126-1134.

12. Yü TF, Gutman AB. Efficacy of colchicine prophylaxis in gout: prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961; 55: 179-192.

13. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout: a placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974; 17:609-614.

14. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004; 31:2429-2432.

15. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009; 38:411-419.

16. Yang LPH. Oral colchicine (Colcrys®) in the treatment and prophylaxis of gout. Drugs. 2010; 70:1603-1613.

17. Terkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011; 63:2226-2237.

18. Davis MW, Wason S, DiGiacinto JL. Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating gout. Consult Pharm. 2013; 28:176-183.

19. Ryu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users [published online ahead of print January 24, 2013]. J Clin Pharmacol. doi: 10.1177/0091270011439715.

20. Kuncl RW, Duncan G, Watson, Alderson K, Rogawsky MA, Peper M. Colchicine miopathy and neuropathy. N Engl J Med. 1987; 25:1552-1568.

21. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol. 2006; 12:275-276.

22. Schlesinger N, Moore DF, Sun JD, Schumacher HR Jr. A survey of current evaluation and treatment of gout. J Rheumatol. 2006; 33:2050-2052.

23. Perez-Ruiz F, Carmona L, Yebeñes MJG, et al; on behalf of the GEMA Study Group, Sociedad Espanola de Reumatologia. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the Gout Evaluation and Management study. J Clin Rheumatol. 2011; 17:349-355.

24. Perez-Ruiz F, Gonzalez Mielgo FJ, Herrero-Beites AM . Optimisation of the treatment of acute gout. BioDrugs. 2000; 13:45-53.

25. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med. 1987; 17:301-304.

26. Grahame R. Is there still a place for colchicine in the treatment of acute gout? Int J Clin Pract. 2007; 61:1966-1967.

27. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010; 62:1060-1068.

28. Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010; 11:2933-2938.

29. Gaffo AL, Schumacher HR, Saag KG, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012; 64:1508-1517.

30. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol. 1993; 20:111-113.

31. Man CY, Cheung IT F, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007; 49:670-677.

32. Janssens HJ, Lucassen PLBJ, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008:CD005521.

33. Janssens HJEM, Janssen M, van de Lisdonk EH, van Riel PLCM, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008; 371:1854-1860.

34. Vazquez-Mellado J, Cuan A, Magana M, et al. Intradermal tophi in gout: a case-control study. J Rheumatol. 1999; 26:136-140.

35. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol. 1999; 26:2285-2286.

36. Gutman AB, Yü TF. Effects of adrenocorticotropic hormone (ACT H) in gout. Am J Med. 1950; 9:24-30.

37. Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 2002; 46:2765-2775.

38. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988; 31:803-805.

39. Perez-Ruiz F, Herrero-Beites AM. ACTH analogues medications for the treatment of crystalinduced acute inflammation. A target to be explored? [published online ahead of print March 19, 2013] Joint Bone Spine. doi: 10.1016/j.jbspin.2013.01.009.

40. Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP . ACT H as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine. 2013; 80:291-294.

41. So A, Busso N. A magic bullet for gout? Ann Rheum Dis. 2009; 68; 1517-1519.

42. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007; 9:R28.

43. Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial [published online ahead of print March 13, 2013]. Rheumatology (Oxford). doi: 10.1093/rheumatology/ket114.

44. Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results of the presurge-1 trial. Arthritis Care Res (Hoboken). 2012; 64:1462-1470.

45. Terkeltaub RA, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013; 15:R25.

46. Schlesinger N, Schumacher HR, Bardin T, et al. Efficacy of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients: results of the B-Relieved II study (response in acute flare and in prevention of episodes of re-flare in gout). Ann Rheum Dis. 2011; 70(suppl 3):186. Abstract THU0019.

47. So A, Alten R, Bardin T, et al. A controlled trial of canakinumab vs triamcinolone acetonide in acute gouty arthritis patients: results of the B-Relieved study (response in acute flare and in prevention of episodes of re-flare in gout). Ann Rheum Dis. 2011; 70(suppl 3):104. Abstract OP 0108.

Medicine Matters Rheumatology

Abstract